Home › Research › Biomarkers
Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease
Therriault J, Servaes S, Tissot C, Rahmouni N, Ashton NJ, Benedet AL, Karikari TK, Macedo AC et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023-04-20
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Introduction Plasma biomarkers are promising tools for Alzheimer's disease (AD) diagnosis, but comparisons with more established biomarkers are needed. Methods We assessed the diagnostic performance of p-tau 181 , p-tau 217 , and p-tau 231 in plasma and CSF in 174 individuals evaluated by dementia specialists and assessed with amyloid-PET and tau-PET. Receiver operating characteristic (ROC) analyses assessed the performance of plasma and CSF biomarkers to identify amyloid-PET and tau-PET positivity. Results Plasma p-tau biomarkers had lower dynamic ranges and effect sizes compared to CSF p-tau. Plasma p-tau 181 (AUC = 76%) and p-tau 231 (AUC = 82%) assessments performed inferior to CSF p-tau 181 (AUC = 87%) and p-tau 231 (AUC = 95%) for amyloid-PET positivity. However, plasma p-tau 217 (AUC = 91%) had diagnostic performance indistinguishable from CSF (AUC = 94%) for amyloid-PET positivity. Discussion Plasma and CSF p-tau 217 had equivalent diagnostic performance for biomarker-defined AD. Our results suggest that plasma p-tau 217 may help reduce the need for invasive lumbar punctures without compromising accuracy in the identification of AD. Highlights p-tau 217 in plasma performed equivalent to p-tau 217 in CSF for the diagnosis of AD, suggesting the increased accessibility of plasma p-tau 217 is not offset by lower accuracy. p-tau biomarkers in plasma had lower mean fold-changes between amyloid-PET negative and positive groups than p-tau biomarkers in CSF. CSF p-tau biomarkers had greater effect sizes than plasma p-tau biomarkers when differentiating between amyloid-PET positive and negative groups. Plasma p-tau 181 and plasma p-tau 231 performed worse than p-tau 181 and p-tau 231 in CSF for AD diagnosis.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Therriault, J., Servaes, S., Tissot, C., Rahmouni, N., Ashton, N. J., Benedet, A. L., et al. (2023). Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.13026
Vancouver
Therriault J, Servaes S, Tissot C, Rahmouni N, Ashton NJ, Benedet AL, et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023. doi:10.1002/alz.13026. PMID: 37078495.
BibTeX
@article{therriault2023-37078495,
author = {Therriault, J. and Servaes, S. and Tissot, C. and Rahmouni, N. and Ashton, N. J. and Benedet, A. L. and Karikari, T. K. and Macedo, A. C. and others},
title = {{Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2023},
doi = {10.1002/alz.13026},
pmid = {37078495},
url = {https://doi.org/10.1002/alz.13026}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Plasma p-tau biomarkers had lower dynamic ranges and effect sizes compared to CSF p-tau.
- Our results suggest that plasma p-tau 217 may help reduce the need for invasive lumbar punctures without compromising accuracy in the identification of AD.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants174
- Evidence strengthLow
How this study scored 52/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 30 of the 58 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 174 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37078495) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 30 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 30 of the 58 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.